Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 28c
May 7, 2019 6:54 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.01, $0.28 better than the analyst estimate of $0.73. Revenue for the quarter came in at $49.8 million versus the consensus estimate of $47.07 million.
2019 Expense Guidance
R&D spend in 2019, on a non-GAAP basis, is expected to be... More